Texas Sues J&J, Kenvue Over Tylenol
Analysis based on 20 articles · First reported Oct 28, 2025 · Last updated Oct 29, 2025
The lawsuit by United States — Texas against Johnson & Johnson and Kenvue has negatively impacted their stock prices, with Kenvue shares falling 2.4% and Johnson & Johnson shares falling 1.6%. This event creates uncertainty for the pharmaceutical industry, particularly for companies manufacturing over-the-counter medications, due to potential legal precedents and increased scrutiny over product safety claims.
United States — Texas Attorney General Ken Paxton has filed a lawsuit against Johnson & Johnson and its spin-off Kenvue, alleging that they deceptively marketed Tylenol to pregnant women and concealed its supposed links to autism and attention deficit hyperactivity disorder (ADHD). The lawsuit, filed in Panola County, United States — Texas, seeks civil penalties and demands the destruction of marketing materials claiming Tylenol is safe for pregnant women. Kenvue has vehemently denied the claims, asserting Tylenol's safety and pledging to vigorously defend itself. Johnson & Johnson stated that Kenvue is responsible for liabilities related to over-the-counter products. This legal action follows recent public claims by Donald Trump regarding Tylenol's unproven link to autism, which medical experts and organizations like the American College of Obstetricians and Gynecologists have refuted, emphasizing acetaminophen's safety and importance during pregnancy. The lawsuit also accuses Johnson & Johnson of fraudulent transfer by spinning off Kenvue to shield itself from liability. Shares of both Johnson & Johnson and Kenvue experienced declines following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard